Quantcast

Latest Boston Scientific Corporation Stories

2014-08-29 16:24:07

Large, Prospective, Multi-National Study Examines Management of Benign Biliary Strictures with Fully Covered Self-Expanding Metal Stents after Extended Indwell MARLBOROUGH, Mass., Aug. 29, 2014 /PRNewswire/ -- A Boston Scientific Corporation (NYSE: BSX) prospective, multinational study on stent removability and preliminary long term stricture resolution of benign biliary strictures has been published in the August issue of the peer-reviewed journal, Gastroenterology. The multinational...

2014-08-25 16:27:13

MALBOROUGH, Mass., Aug. 25, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New York, NY. Mike Mahoney, chief executive officer, and Dan Brennan, executive vice president and chief financial officer, will participate in a 35-minute question and answer session regarding the company beginning at approximately 9:55 a.m. ET. A live webcast of the question and answer...

2014-08-19 04:22:48

Companies Reach Agreement to Develop a New and Differentiated FFR Guidewire and Next Generation Boston Scientific Rotablator(TM) RotaWire(TM) MARLBOROUGH, Mass. and NAGOYA, Japan, Aug. 19, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized plans to develop a new, differentiated fractional flow reserve (FFR) wire. The joint project focuses on creating a device intended...

2014-08-07 12:30:17

High performance workspace design provides open, state-of-the-art office environment BOSTON, Aug. 7, 2014 /PRNewswire/ -- Margulies Perruzzi Architects (MPA), one of Boston's most innovative architectural and interior design firms, announced that it has completed the new global headquarters for Boston Scientific Corporation, a worldwide developer, manufacturer and marketer of medical solutions. MPA provided corporate architecture and interior design services for the new 110,000 SF,...

2014-07-24 08:32:46

MARLBOROUGH, Mass., July 24, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to $1.890 billion. This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses) and 4 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted...

2014-07-23 16:28:13

Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease MARLBOROUGH, Mass., July 23, 2014 /PRNewswire/ -- Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent(TM) Paclitaxel-Coated PTCA Balloon Catheter. The Agent Drug-Coated Balloon (DCB) provides physicians with an...

2014-07-22 08:32:41

Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products MARLBOROUGH, Mass., July 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS(TM) Imaging System. This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products. The POLARIS System offers enhanced ease-of-use...

2014-07-21 16:26:15

Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients MARLBOROUGH, Mass., July 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL(TM) Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease (CAD). Bare-metal stents continue to play an important role in the treatment of CAD and represent a...

2014-07-14 20:21:24

European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus(TM) Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes. "Having the 25 mm size allows us to be more precise in selecting the...

2014-07-14 08:27:37

Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger(TM) Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Ranger Drug-Coated Balloon (DCB)...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related